Key Sessions
Phyllis Arthur
COVID-19 therapeutics: Modality, efficacy and implications for access
Biotechnology Innovation Organization (BIO)
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Day 4 - Live Sessions
keyboard_arrow_leftSearch & Filter
search
Streams
Formats
Topics
Day 4 - Live Sessions
search
Streams
Formats
Topics
On Demand
Networking
BIO-Europe Digital 2020 Networking: Introducing the 24/7 Café
10:00 - 10:3030 mins
Networking
BIO-Europe Digital 2020 Networking: Long-lasting partnerships are like happy marriages
- Urs Schleuniger - Global Head Alliance & Asset Management, Roche Pharma Partnering
11:00 - 12:0060 mins
Additional Program
EIT Health Headstart : Cohort A
- Sebastião van Uden - CEO, Bac3Gel
- Sara Lobo - Co-founder and CMO, C-mo Medical Solutions
- Cornel Amariei - Founder, DOTLUMEN
- Massimiliano Clamer - Founder and President, IMMAGINA BioTechnology
- Alfonso Maria Ponsiglione - Co-founder and COO, Kyme NanoImaging
- David Breitenbach - Co-founder, Sineko Global
- Ivan Porro - Founder and CEO, SurgiQ
- Daniele Conti - Co-founder and CEO, SYNDIAG
15:30 - 16:1545 mins
Additional Program
EIT Health Headstart : Cohort B
- Eugene Nayshtetik - Founder and Managing Partner, Lorton Investments - SenceBand
- Katarzyna Zimoląg - CEO, i-Care
- Riccardo Piccioli - Co-founder and CEO, Mysurable
17:00 - 18:0060 mins
Plenary
COVID-19 therapeutics: Modality, efficacy and implications for access
- Phyllis Arthur - VP, Infectious Disease and Vaccine Policy, Biotechnology Innovation Organization (BIO)
- David Thomas - VP, Industry Research and Analysis, Biotechnology Industry Organization (BIO)
- Richard Marsden - CEO, Synairgen
- Neil Mulcock - VP, Government Affairs, EMEA, Gilead Sciences
- Kylie O'Keefe - VP, Global Commercial Strategy, PTC Therapeutics
- Gregg Szabo - VP and Commercial Leader, Virology/Immunology, MSD
Get the latest news.
As it happens
Sign up to get the latest on the agenda and speakers.
Filter
Streams
Formats
Topics